About us

The Transgenics & Gene Targeting Facility at the BSRC Al. Fleming was established in 2001 to integrate transgenic technologies in the mouse for cutting-edge biomedical research.

The Facility generates transgenic mice via:

• Pronuclear Injection-Founder Generation (certified with ISO 9001:2000 since 2008)
• Embryonic Stem Cell Gene Targeting-Blastocyst Injection-Chimera Production- Germline transmission

In addition the facility has established a CryoUnit which supports the transportation, storage and archiving of mutant strains, through embryo rederivation and cryopreservation, as well as recovery of mouse embryo and sperm. The CryoUnit is member of the European Mouse Mutant Archive network since 2010.

The Facility benefits from the research environment of BSRC “Al.Fleming” to provide an excellent service in transgenic technologies.

Interested parties are welcome to go through our procedure pages and order forms. Pricing inquires can be forwarded to transgenics@fleming.gr.

Dimitris L. Kontoyiannis, Ph.D.
Scientist in Charge

kontoyiannis@fleming.gr (+30) 210.9656310


Demetris Vassilakos, PhD.
Operations Manager – Gene Targeting Specialist

vassilakos@fleming.gr (+30) 210.9656310


Konstantinos Bozonelos, M.Sc.
Cryopreservation Specialist

bozonelos@fleming.gr (+30) 210.9656310


Panagiotis Papadopoulos
Animal Technologist/Transgenics Specialist

ppapadopoulos@fleming.gr (+30) 210.9656310


Vasileios Ntafis, DVM, PhD.
Supervising Veterinarian

ntafis@fleming.gr (+30) 210.9656310

ES cell technology services


Trompouki E, Tsagaratou A, Kosmidis SK, Dollé P, Qian J, Kontoyiannis DL, Cardoso WV, Mosialos G. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia. (2009) May;11(5):469-76.
Fotopoulou S, Oikonomou N, Grigorieva E, Nikitopoulou I, Paparountas T, Thanassopoulou A, Zhao Z, Xu Y, Kontoyiannis DL, Remboutsika E, Aidinis V. ATX expression and LPA signalling are vital for the development of the nervous system. Dev Biol. (2010) Mar 15;339(2):451-64.
Papadaki O, Milatos S, Grammenoudi S, Mukherjee N, Keene JD, Kontoyiannis DL. Control of thymic T cell maturation, deletion and egress by the RNA-binding protein HuR. J Immunol. (2009) Jun 1;182(11):6779-88.
Katsanou V, Milatos S, Yiakouvaki A, Sgantzis N, Kotsoni A, Alexiou M, Harokopos V, Aidinis V, Hemberger M, Kontoyiannis DL. The RNA-binding protein Elavl1/HuR is essential for placental branching morphogenesis and embryonic development. Mol Cell Biol. (2009) May; 29(10):2762-76
Tzima S, Victoratos P, Kranidioti K, Alexiou M, Kollias G. Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production. J Exp Med. (2009) May 11;206(5):1167-79.
Papadaki C, Alexiou M, Cecena G, Verykokakis M, Bilitou A, Cross JC, Oshima RG, Mavrothalassitis G.
Transcriptional repressor Erf determines extraembryonic ectoderm differentiation.
Mol Cell Biol. (2007) Jul; 27(14): 5201-13
Victoratos P, Lagnel J, Tzima S, Alimzhanov MB, Rajewsky K, Pasparakis M, Kollias G.
FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses.
Immunity (2006) Jan; 24 (1): 65-77


DNA microinjection service


Panagopoulou P, Davos CH, Milner DJ, Varela E, Cameron J, Mann DL, Capetanaki Y. Desmin mediates TNF-alpha-induced aggregate formation and intercalated disk reorganization in heart failure. J Cell Biol. 2008 Jun 2;181(5):761-75.
Katsanou V, Papadaki O, Milatos S, Blackshear PJ, Anderson P, Kollias G, Kontoyiannis DL.
HuR as a negative posttranscriptional modulator in inflammation.
Mol. Cell (2005) Sep; 19(6): 777-89
Panagopoulos D, Victoratos P, Alexiou M, Kollias G, Mosialos G.
Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo.
J Virol. (2004) Dec; 78(23):13253-61.


Archiving services


Poulou M, Bell D, Bozonelos K, Alexiou M, Gavalas A, Lovell-Badge R, Remboutsika E. Development of a chromosomally integrated metabolite-inducible Leu3p-alpha-IPM “off-on” gene switch. PLoS One. 2010 Aug 31;5(8)